The International Society of Organoid Research convened the 2026 Organoid Clinical Transformation Summit in Hangzhou, China, on Aug. 18 [1].
This initiative marks a critical shift toward integrating lab-grown organoids into standard medical practice. By establishing formal guidelines, the industry aims to move from theoretical biological models to credible evidence that can influence patient care.
During the summit, the organization launched the International Center for Organoid Research and Enterprise, known as ICORE [1]. The new center began operations with nine founding member companies [1]. These partners intend to collaborate on the technical and regulatory hurdles required to bring organoid technology into clinics.
The summit operated under the theme "From Biological Models to Credible Evidence — Standardization and Clinical Practice of Organoids" [2]. Participants focused on the necessity of creating uniform protocols to ensure that organoid-based tests are reproducible across different laboratories and jurisdictions.
Organoids are miniature, simplified versions of organs produced in vitro. While they have long been used in research, the transition to clinical application requires rigorous standardization to ensure safety and efficacy [2]. The launch of ICORE is intended to bridge the gap between academic discovery and commercial enterprise.
By centering the summit in Hangzhou, the International Society of Organoid Research highlighted the role of global cooperation in biotechnology. The collaboration between the nine founding companies is expected to accelerate the development of standardized benchmarks for organoid quality and performance [1].
“The new center began operations with nine founding member companies.”
The establishment of ICORE suggests that the organoid field is moving out of the purely experimental phase and into a commercialization phase. By focusing on standardization, the industry is attempting to create a regulatory framework that would allow organoids to potentially replace some animal testing or provide personalized drug screening for patients in a clinical setting.
